Leadership Pittsburgh Inc. Announces CEO Transition
Leadership Pittsburgh Inc. Board Chair
Under Beer's leadership, the organization has expanded programming for alumni, increased corporate and foundation funding, and successfully navigated a comprehensive rebrand. Her tenure has been marked by a strong focus on community engagement – including a broader regional scope – and advancing the organization's overall mission to strengthen regional leadership through programs, partnerships, and connections.
"Serving as CEO of Leadership Pittsburgh Inc. for the past four years has been one of the greatest honors of my professional life," said Beer. "This organization plays a vital role in strengthening civic leadership across our entire region, and choosing to leave was a difficult decision. I am incredibly proud of what our staff, board, partners, and supporters have achieved together, and I am committed to ensuring a thoughtful and seamless transition. This organization and all those involved mean a lot to me, and I look forward to watching it continue to strengthen and serve our region in meaningful ways."
The Board of Directors will initiate a comprehensive search process for the organization's next leader, and Beer will remain in her role, working closely with the Board and Leadership Pittsburgh Inc. staff to ensure continuity and stability.
ABOUT LEADERSHIP PITTSBURGH INC. (LPI)
Leadership Pittsburgh Inc. (LPInc.) is an independent nonprofit organization dedicated to developing a diverse group of leaders to serve
For Information:
Leadership
Deputy General Counsel, PNC
c/o:
[email protected]
412-952-4880
View original content:https://www.prnewswire.com/news-releases/leadership-pittsburgh-inc-announces-ceo-transition-302708444.html
SOURCE Leadership Pittsburgh Inc.; KOPPERS HOLDINGS INC.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and
- Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
- Consumer Safety Alert: CPSC Warns Consumers About Fake and Counterfeit Squishy Toys; Reiterates Warning About Serious Burn Hazards
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share